GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

emvistegrast   Click here for help

GtoPdb Ligand ID: 14189

Synonyms: example 356 [WO2020092375] | GS-1427 | GS1427
Compound class: Synthetic organic
Comment: Emvistegrast (GS-1427) is an oral α4/β7 integrin inhibitor. It was designed to reduce α4β7 integrin-mediated recruitment of α4β7-expressing lymphocytes to the gut, as disease-modifying mechanism for inflammatory bowel disease. GS-1427 is one of the inhibitors claimed in patent WO2020092375A1 [1].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 12
Hydrogen bond donors 1
Rotatable bonds 11
Topological polar surface area 133.21
Molecular weight 708.66
XLogP 1.87
No. Lipinski's rules broken 2

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

SMILES / InChI / InChIKey
Click here for help
Canonical SMILES CCOC(=O)[C@H](CC1=CC=C(C2=NC=CC=C12)N3C(=O)C4=CC=NC=C4N(C)C3=O)NC(=O)C5=C(C)C=C(C=C5F)N6CCOC[C@@H]6C(F)(F)F
Isomeric SMILES CCOC(=O)[C@H](CC1=CC=C(N2C(=O)N(C)C3=C(C=CN=C3)C2=O)C4=C1C=CC=N4)NC(=O)C5=C(C)C=C(C=C5F)N6CCOC[C@@H]6C(F)(F)F
InChI InChI=1S/C35H32F4N6O6/c1-4-51-33(48)25(42-31(46)29-19(2)14-21(16-24(29)36)44-12-13-50-18-28(44)35(37,38)39)15-20-7-8-26(30-22(20)6-5-10-41-30)45-32(47)23-9-11-40-17-27(23)43(3)34(45)49/h5-11,14,16-17,25,28H,4,12-13,15,18H2,1-3H3,(H,42,46)/t25-,28+/m0/s1
InChI Key UQXAGOKYXPMBEP-LBNVMWSVSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

References
1. Blomgren PA, Campbell T, Chandrasekhar J, Clark CT, Codelli JA, Currie KS, Kropf JE, Moazami Y, Nava N, Patel L et al.. (2020)
Quinoline derivatives as alpha4beta7 integrin inhibitors.
Patent number: WO2020092375A1. Assignee: Gilead Sciences, Inc.. Priority date: 29/10/2019. Publication date: 07/05/2020.